Meyer, Bernhard M.
Rabl, Ulrich
Huemer, Julia
Bartova, Lucie
Kalcher, Klaudius
Provenzano, Julian
Brandner, Christoph
Sezen, Patrick
Kasper, Siegfried
Schatzberg, Alan F.
Moser, Ewald http://orcid.org/0000-0001-8278-9583
Chen, Gang
Pezawas, Lukas http://orcid.org/0000-0002-1329-6352
Article History
Received: 12 June 2018
Revised: 3 January 2019
Accepted: 10 January 2019
First Online: 4 February 2019
Conflict of interest
: Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Alan F. Schatzberg reports conflicts of interest. Consultant: Bay City Capital, CeNeRx, Cervel, Clintara, Depomed, Eli Lilly, Forum (EnVivo), Genentech, Gilead, Jazz, Lundbeck/Takeda, McKinsey, MSI, Myriad Genetics, Naurex, Neuronetics, One Carbon, Pfizer, PharmaNeuroBoost, Sunovion, Xhale. Intellectual property: Named inventor on pharmacogenetic use patents on prediction of antidepressant response and glucocorticoid antagonists in psychiatry. Equity: Amnestix, CeNeRx, Corcept (co-founder), Forest Labs, Gilead, Incyte, Merck, Neurocrine, Pfizer, PharmaNeuroBoost, Seattle Genetics, Synosia, Titan, Xhale. The remaining authors declare that they have no conflict of interest.